Published in J Virol on November 01, 1998
Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol (1999) 1.32
Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20
Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J Virol (1999) 1.10
Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection. J Virol (2001) 1.01
Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model. Retrovirology (2011) 0.89
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci U S A (1997) 2.20
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol (1990) 1.83
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
The influence of virus structure on antibody responses and virus serotype formation. Immunol Today (1996) 1.50
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18
Influence of the murine MHC (H-2) on Friend leukemia virus-induced immunosuppression. J Exp Med (1986) 1.15
Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med (1988) 1.11
Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology (1998) 1.08
Differing T-cell requirements for recombinant retrovirus vaccines. J Virol (1996) 1.02
Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol (1991) 1.01
The role of cytotoxic T lymphocytes in infectious disease: history, criteria, and state of the art. Curr Top Microbiol Immunol (1994) 0.93
Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia. J Virol (1994) 0.87
Variable regions of antibodies to synthetic polypeptides--III. Antibodies arising in response to administration of anti-idiotope. Mol Immunol (1992) 0.80
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Regulation of the bacterial cell wall: analysis of a mutant of Bacillus subtilis defective in biosynthesis of teichoic acid. J Bacteriol (1972) 5.55
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Asia Pacific consensus recommendations for colorectal cancer screening. Gut (2008) 3.19
A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest (2001) 3.18
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage (1997) 2.29
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ (1993) 2.24
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Pathogenesis of the urethral syndrome in women and its diagnosis in general practice. Lancet (1972) 2.21
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
The management of suspected urinary tract infection in general practice. Br J Gen Pract (1990) 1.76
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev (2005) 1.69
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66
The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64
Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62
Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61
Preliminary report on isolation of mycobacteria from patients with Crohn's disease. Dig Dis Sci (1989) 1.60
Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. Chest (1999) 1.59
Towards the reality of the primary health care team: an educational approach. J R Coll Gen Pract (1981) 1.57
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol (1994) 1.50
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Symptomatic urinary infection in childhood: presentation during a four-year study in general practice and significance and outcome at seven years. J R Coll Gen Pract (1977) 1.47
Purification and ultrastructure of Aleutian disease virus of mink. Nature (1975) 1.47
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Should the endurance shuttle walk test replace the six-minute walk test in individuals with chronic obstructive pulmonary disease? Chron Respir Dis (2006) 1.41
Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol (1976) 1.41
Internal fixation of wrist fractures. J R Soc Med (1978) 1.39
Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol (2000) 1.39
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol (1989) 1.38
Statement on withholding and withdrawing life-sustaining therapy. S Afr Med J (1994) 1.38
Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther (1996) 1.38
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem (1998) 1.35
Sequences in the U5-gag-pol region influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J Virol (1990) 1.34
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther (2000) 1.28
Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J Gen Virol (1988) 1.28
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Change in host cell tropism associated with in vitro replication of equine infectious anemia virus. J Virol (1989) 1.28
Who uses the Smoker's Quitline in Massachusetts? Tob Control (2002) 1.27
Pseudotyping of dual-tropic recombinant viruses generated by infection of mice with different ecotropic murine leukemia viruses. Virology (1985) 1.25
Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J Virol (1990) 1.24
Pressure-volume index in head injury. J Neurosurg (1987) 1.23
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18
Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol (1985) (1995) 1.18
Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration. J Virol (1986) 1.18
Characterization of a neurologic disease induced by a polytropic murine retrovirus: evidence for differential targeting of ecotropic and polytropic viruses in the brain. J Virol (1995) 1.18
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Murine leukemia virus infectious centers are dependent on the rate of virus production by infected cells. Virology (1978) 1.16
Nutritional support for individuals with COPD: a meta-analysis. Chest (2000) 1.16
Influence of the murine MHC (H-2) on Friend leukemia virus-induced immunosuppression. J Exp Med (1986) 1.15